GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PELL Bio-Med Technology Co Ltd (TPE:6949) » Definitions » Net Current Asset Value

PELL Bio-Med Technology Co (TPE:6949) Net Current Asset Value : NT$8.39 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is PELL Bio-Med Technology Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

PELL Bio-Med Technology Co's net current asset value per share for the quarter that ended in Mar. 2025 was NT$8.39.

The historical rank and industry rank for PELL Bio-Med Technology Co's Net Current Asset Value or its related term are showing as below:

TPE:6949' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.08   Med: 7.76   Max: 17.04
Current: 15.85

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of PELL Bio-Med Technology Co was 17.04. The lowest was 4.08. And the median was 7.76.

TPE:6949's Price-to-Net-Current-Asset-Value is ranked worse than
85.35% of 983 companies
in the Biotechnology industry
Industry Median: 3.86 vs TPE:6949: 15.85

PELL Bio-Med Technology Co Net Current Asset Value Historical Data

The historical data trend for PELL Bio-Med Technology Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PELL Bio-Med Technology Co Net Current Asset Value Chart

PELL Bio-Med Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
-0.65 8.44 15.39 10.26

PELL Bio-Med Technology Co Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.89 17.52 15.21 10.26 8.39

Competitive Comparison of PELL Bio-Med Technology Co's Net Current Asset Value

For the Biotechnology subindustry, PELL Bio-Med Technology Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PELL Bio-Med Technology Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PELL Bio-Med Technology Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where PELL Bio-Med Technology Co's Price-to-Net-Current-Asset-Value falls into.


;
;

PELL Bio-Med Technology Co Net Current Asset Value Calculation

PELL Bio-Med Technology Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1157.729-458.617-106.291-0)/57.802
=10.26

PELL Bio-Med Technology Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1046.766-454.868-104.801-0)/58.079
=8.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PELL Bio-Med Technology Co  (TPE:6949) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


PELL Bio-Med Technology Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of PELL Bio-Med Technology Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


PELL Bio-Med Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell).

PELL Bio-Med Technology Co Headlines

No Headlines